The inconsistency between pre-clinical studies and clinical trials on Bcl-2 inhibitors confirms the necessity of identifying biomarkers capable of predicting which cancers would benefit from treatment with Bcl-2 inhibitors [18]; whether Bcl-2 expression itself has such a predictive value in non squamous NSCLC remains to be determined. This evidence concerns the gene BCL2 and non-small cell lung carcinoma.